Exploring the Advantages & Disadvantages of Combination Therapies in Improving Clinical Trial Outcomes & Tumour Targeting

• Evaluating how combination therapies can enhance tumour-specific immune responses
• Overcoming challenges with increased toxicity, complex dosing schedules, and variable patient responses to maximise effectiveness of combined regimens
• Discussing strategies to optimise trial design, biomarker selection, and patient stratification to maximise the benefits of combination therapies

Speakers:

Alfred Slanetz

President & Chief Executive Officer

Geneius Inc.